NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AKRO

Akero Therapeutics Inc

Jun 30 • 04:00PM ET

53.36

Dollar change -2.83
Percentage change -5.04	%

Healthcare • Biotechnology • USA • NASD

Peers: MDGL ARWR HALO GNFT ALLK VKTX NBIX ENTA GALT SLDB

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT SURI

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.75	Insider Own	9.99%	Shs Outstand	79.67M	Perf Week	-1.24%
Market Cap	4.25B	Forward P/E	-	EPS next Y	-4.36	Insider Trans	-2.31%	Shs Float	71.76M	Perf Month	11.10%
Enterprise Value	3.60B	PEG	-	EPS next Q	-0.90	Inst Own	101.98%	Short Float	10.80%	Perf Quarter	24.91%
Income	-269.44M	P/S	-	EPS this Y	-1.23%	Inst Trans	21.98%	Short Ratio	4.64	Perf Half Y	86.83%
Sales	0.00M	P/B	3.92	EPS next Y	-14.90%	ROA	-26.06%	Short Interest	7.75M	Perf YTD	91.80%
Book/sh	13.60	P/C	6.20	EPS next 5Y	-10.29%	ROE	-27.92%	52W High	58.40 -8.63%	Perf Year	132.71%
Cash/sh	8.61	P/FCF	-	EPS past 3/5Y	-9.07% -5.28%	ROIC	-24.21%	52W Low	21.02 153.85%	Perf 3Y	397.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.76% 4.79%	Perf 5Y	104.29%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-17.04%	Oper. Margin	-	ATR (14)	2.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.80	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.80	EPS Q/Q	0.02%	SMA20	-1.55%	Beta	-0.14	Target Price	73.20
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	12.62%	Rel Volume	1.00	Prev Close	56.19
Employees	63	LT Debt/Eq	0.03	Earnings	May 12 BMO	SMA200	38.88%	Avg Volume	1.67M	Price	53.36
IPO	Jun 20, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.17% -	Trades		Volume	1,668,160	Change	-5.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy	$35 → $63
Jan-27-25	Reiterated	H.C. Wainwright	Buy	$50 → $72
Nov-18-24	Initiated	Citigroup	Buy	$65
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28

Show Previous Ratings

Jun-03-25 07:00AM	Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-28-25 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 11:51PM	Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today (Insider Monkey) +24.72%
May-13-25 08:10AM	Best Biotech Stocks to Buy in 2025 (MarketBeat)
May-12-25 07:00AM	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
05:21PM	Loading…
May-11-25 05:21PM	Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now (Insider Monkey)
May-10-25 10:00AM	Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 (GlobeNewswire)
May-09-25 07:41AM	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 (GlobeNewswire) -5.99%
07:11AM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine (GlobeNewswire)
May-07-25 04:05PM	Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference (GlobeNewswire)
Apr-30-25 07:00AM	Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 (GlobeNewswire) +5.97%
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-06-25 01:47PM	Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (Seeking Alpha)
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
09:34AM	Loading…
Mar-02-25 09:34AM	Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 01:23PM	Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-23-25 03:18PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-20-25 08:42AM	Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ) (GlobeNewswire)
Feb-19-25 02:45PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
Feb-03-25 07:25PM	Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 (Insider Monkey)
12:28PM	Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High (Insider Monkey)
Feb-02-25 06:21PM	This Stock Just Doubled in 1 Day -- Is It Still a Buy? (Motley Fool)
04:35PM	Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now? (Insider Monkey)
Jan-30-25 04:05PM	Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive)
Jan-28-25 09:30PM	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
11:14AM	Akeros cirrhosis treatment shows promise in Phase IIb study (Clinical Trials Arena)
08:40AM	Why Akero Therapeutics Inc. (AKRO) Surged on Monday (Insider Monkey)
04:24PM	Loading…
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +97.52%
04:01PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:13PM	Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data (GuruFocus.com)
11:27AM	Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results (Investopedia)
11:10AM	Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal (GuruFocus.com)
10:57AM	Akero Therapeutics Stock Doubles on Liver Data (Barrons.com)
09:01AM	Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why (Benzinga)
06:30AM	Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study (GlobeNewswire)
Jan-24-25 04:05PM	Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jan-13-25 07:00AM	Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD (GlobeNewswire) -8.90%
Jan-09-25 12:18PM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Jan-07-25 07:00AM	Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-24 12:59PM	Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-26-24 07:00AM	Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-24 11:00AM	Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire) -5.61%
Nov-13-24 04:05PM	Akero Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-12-24 11:00PM	Akero Therapeutics Advances in MASH Treatment Trials (TipRanks)
Nov-08-24 07:00AM	Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:06AM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims of Misconduct on Your Behalf (Newsfile)
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-21-24 07:00AM	Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-17-24 03:02PM	State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares (GuruFocus.com)
Oct-16-24 08:44AM	Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin (Insider Monkey)
Oct-15-24 06:10PM	Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds (Insider Monkey)
Sep-30-24 07:00AM	Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-12-24 01:12AM	Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc (GuruFocus.com)
Sep-09-24 07:00AM	Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH (GlobeNewswire)
Sep-05-24 12:02AM	Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 04:05PM	Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-24 02:53PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-16-24 12:00PM	Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-28-24 10:40AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-24-24 01:04PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-21-24 11:06AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) +6.52%
Jun-19-24 02:45PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-17-24 10:23AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-13-24 03:57PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-11-24 07:00AM	Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jun-10-24 10:14AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-08-24 08:15AM	Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 (GlobeNewswire)
Jun-06-24 10:39AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-03-24 09:57AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-30-24 09:16PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-29-24 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 02:12PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) -7.76%
May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.00%
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cheng Andrew	President and CEO	Jun 18 '25	Sale	54.84	6,620	363,041	549,867	Jun 20 09:09 PM
Gangloff Scott A.	Chief Technology Officer	Jun 18 '25	Sale	54.84	848	46,504	23,452	Jun 20 09:08 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 20 '25	Sale	54.59	875	47,766	31,698	Jun 20 09:08 PM
Rolph Timothy	Chief Scientific Officer	Jun 18 '25	Sale	54.84	1,129	61,914	166,234	Jun 20 09:07 PM
White William Richard	Chief Financial Officer	Jun 18 '25	Sale	54.84	1,634	89,609	57,521	Jun 20 09:07 PM
Yale Catriona	Chief Development Officer	Jun 18 '25	Sale	54.84	1,633	89,554	90,598	Jun 20 09:07 PM
Young Jonathan	Chief Operating Officer	Jun 18 '25	Sale	54.84	1,453	79,683	196,594	Jun 20 09:06 PM
Yale Catriona	Chief Development Officer	Jun 16 '25	Option Exercise	21.10	10,000	211,000	102,231	Jun 20 09:22 AM
Yale Catriona	Chief Development Officer	Jun 16 '25	Sale	54.23	10,000	542,306	92,231	Jun 20 09:22 AM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 16 '25	Option Exercise	19.87	2,000	39,740	34,573	Jun 20 09:22 AM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 16 '25	Sale	54.14	2,000	108,272	32,573	Jun 20 09:22 AM
Cheng Andrew	President and CEO	Jun 10 '25	Sale	54.05	37,837	2,044,940	556,487	Jun 12 06:34 PM
Rolph Timothy	Chief Scientific Officer	Jun 10 '25	Sale	54.00	2,358	127,323	167,363	Jun 12 06:33 PM
White William Richard	Chief Financial Officer	Jun 10 '25	Sale	53.99	2,804	151,402	59,155	Jun 12 06:33 PM
Yale Catriona	Chief Development Officer	Jun 10 '25	Sale	54.00	2,803	151,351	92,231	Jun 12 06:33 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 10 '25	Sale	54.00	919	49,625	32,573	Jun 12 06:32 PM
Young Jonathan	Chief Operating Officer	Jun 10 '25	Sale	53.99	2,493	134,605	198,047	Jun 12 06:32 PM
Rolph Timothy	Chief Scientific Officer	Jun 06 '25	Option Exercise	21.09	25,000	527,254	194,721	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 05 '25	Option Exercise	21.10	12,500	263,750	182,221	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 06 '25	Sale	55.04	25,000	1,376,000	169,721	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 05 '25	Sale	53.49	12,500	668,634	169,721	Jun 09 05:30 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 02 '25	Option Exercise	19.87	4,000	79,480	37,492	Jun 04 05:36 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 02 '25	Sale	50.31	4,000	201,258	33,492	Jun 04 05:36 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 22 '25	Option Exercise	44.37	4,000	177,480	37,492	May 23 05:30 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 22 '25	Sale	50.00	4,000	200,000	33,492	May 23 05:30 PM
PATRICK D LAMY	Officer	May 22 '25	Proposed Sale	48.35	10,000	483,500		May 22 04:20 PM
Yale Catriona	Chief Development Officer	May 15 '25	Option Exercise	21.10	10,000	211,000	105,034	May 19 07:06 PM
Yale Catriona	Chief Development Officer	May 15 '25	Sale	39.30	10,000	392,978	95,034	May 19 07:06 PM
CATRIONA YALE	Officer	May 15 '25	Proposed Sale	37.88	30,000	1,136,400		May 15 04:27 PM
Cheng Andrew	President and CEO	May 12 '25	Sale	41.48	30,000	1,244,455	594,324	May 13 09:11 PM
Andrew Cheng	Officer	May 12 '25	Proposed Sale	39.85	120,000	4,782,000		May 12 06:47 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Option Exercise	19.87	8,000	158,960	41,492	May 09 07:18 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Sale	42.49	8,000	339,950	33,492	May 09 07:18 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Option Exercise	21.10	12,500	263,750	182,221	May 08 07:34 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Sale	43.43	12,500	542,864	169,721	May 08 07:34 PM
Timothy Rolph	Officer	May 06 '25	Proposed Sale	40.00	50,000	2,000,000		May 06 04:41 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 28 06:22 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Sale	41.03	6,250	256,438	169,721	Apr 28 06:22 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Option Exercise	21.10	9,073	191,440	104,107	Apr 16 06:00 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Sale	37.91	9,073	343,962	95,034	Apr 16 06:00 PM
Cheng Andrew	President and CEO	Apr 10 '25	Sale	35.23	30,000	1,056,780	624,324	Apr 11 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 10 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Sale	35.88	6,250	224,262	169,721	Apr 10 06:00 PM
PATRICK D LAMY	Officer	Apr 07 '25	Proposed Sale	36.73	8,000	293,840		Apr 07 04:24 PM
Graham G. Walmsley	Director	Mar 25 '25	Buy	44.75	91,309	4,085,804	1,091,309	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 26 '25	Buy	43.01	58,691	2,524,417	1,150,000	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 27 '25	Buy	43.55	50,000	2,177,700	1,200,000	Mar 27 07:42 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Option Exercise	21.10	10,000	211,000	105,034	Mar 18 05:30 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Sale	44.76	10,000	447,605	95,034	Mar 18 05:30 PM
Cheng Andrew	President and CEO	Mar 12 '25	Sale	44.88	1,738	78,001	654,324	Mar 14 09:18 PM
Young Jonathan	Chief Operating Officer	Mar 12 '25	Sale	44.88	607	27,242	200,540	Mar 14 08:33 PM
Yale Catriona	Chief Development Officer	Mar 12 '25	Sale	44.88	614	27,556	95,034	Mar 14 08:30 PM
White William Richard	Chief Financial Officer	Mar 12 '25	Sale	44.88	676	30,339	61,959	Mar 14 08:24 PM
Rolph Timothy	Chief Scientific Officer	Mar 12 '25	Sale	44.88	516	23,158	169,721	Mar 14 08:18 PM
Cheng Andrew	President and CEO	Mar 10 '25	Sale	41.77	30,000	1,253,069	656,062	Mar 12 06:00 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Option Exercise	21.10	12,500	263,750	182,737	Mar 07 05:30 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Sale	44.53	12,500	556,590	170,237	Mar 07 05:30 PM
Young Jonathan	Chief Operating Officer	Mar 04 '25	Sale	44.86	50,000	2,243,213	201,147	Mar 05 06:56 PM
Lamy Patrick	Senior VP, Commercial Strategy	Mar 03 '25	Option Exercise	19.87	1,000	19,870	34,492	Mar 05 06:55 PM
Lamy Patrick	Senior VP, Commercial Strategy	Mar 03 '25	Sale	48.09	1,000	48,090	33,492	Mar 05 06:55 PM
Yale Catriona	Chief Development Officer	Feb 18 '25	Option Exercise	21.10	10,000	211,000	105,648	Feb 21 05:31 PM
Yale Catriona	Chief Development Officer	Feb 18 '25	Sale	49.87	10,000	498,660	95,648	Feb 21 05:31 PM
Cheng Andrew	President and CEO	Feb 10 '25	Sale	52.73	30,000	1,581,994	686,062	Feb 11 09:30 PM
Graham G. Walmsley	Director	Jan 30 '25	Buy	48.00	200,000	9,600,000	1,000,000	Feb 07 07:54 PM
Rolph Timothy	Chief Scientific Officer	Feb 05 '25	Option Exercise	21.10	18,750	395,625	188,987	Feb 07 06:05 PM
Rolph Timothy	Chief Scientific Officer	Feb 05 '25	Sale	56.51	18,750	1,059,630	170,237	Feb 07 06:05 PM
Young Jonathan	Chief Operating Officer	Feb 03 '25	Sale	53.81	10,000	538,061	251,147	Feb 05 09:03 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Option Exercise	10.48	53,590	561,807	149,238	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Sale	56.25	53,590	3,014,216	95,648	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Option Exercise	21.10	49,074	1,035,461	144,722	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Sale	55.72	49,074	2,734,212	95,648	Jan 31 09:14 AM
Rolph Timothy	Chief Scientific Officer	Jan 27 '25	Option Exercise	20.51	31,250	640,942	201,487	Jan 29 08:43 PM
Rolph Timothy	Chief Scientific Officer	Jan 27 '25	Sale	55.77	31,250	1,742,958	170,237	Jan 29 08:43 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jan 27 '25	Option Exercise	19.87	4,000	79,480	38,492	Jan 29 08:43 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jan 27 '25	Sale	57.03	5,000	285,150	33,492	Jan 29 08:43 PM
Cheng Andrew	President and CEO	Jan 27 '25	Sale	54.90	30,000	1,646,978	716,062	Jan 29 08:43 PM
Young Jonathan	Chief Operating Officer	Jan 24 '25	Option Exercise	6.36	43,064	274,059	261,147	Jan 27 06:08 PM
Cheng Andrew	President and CEO	Jan 23 '25	Option Exercise	0.61	50,000	30,750	746,062	Jan 27 06:07 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	53,591	1,403,012		Jan 27 04:24 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	69,073	1,808,331		Jan 27 04:24 PM
PATRICK D LAMY	Officer	Jan 27 '25	Proposed Sale	26.18	6,000	157,080		Jan 27 04:23 PM
Andrew Cheng	President, CEO and Director	Jan 27 '25	Proposed Sale	57.03	120,000	6,843,600		Jan 27 04:19 PM
Timothy Rolph	Officer	Jan 27 '25	Proposed Sale	57.03	68,750	3,920,813		Jan 27 04:06 PM
Young Jonathan	Chief Operating Officer	Jan 02 '25	Sale	28.03	10,000	280,330	218,083	Jan 06 02:08 PM
Jonathan Young	Officer	Jan 02 '25	Proposed Sale	27.82	70,000	1,947,400		Jan 02 04:29 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 16 '24	Sale	29.13	1,000	29,130	34,258	Dec 18 09:03 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Option Exercise	21.10	9,074	191,461	104,722	Dec 18 09:01 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Sale	29.11	9,074	264,117	95,648	Dec 18 09:01 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Option Exercise	19.87	3,800	75,506	182,137	Dec 18 08:52 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Sale	31.10	3,800	118,172	178,337	Dec 18 08:52 PM
PATRICK D LAMY	Officer	Dec 16 '24	Proposed Sale	28.89	1,000	28,890		Dec 16 04:30 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Option Exercise	19.87	2,450	48,682	180,787	Dec 12 08:44 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Sale	30.91	4,818	148,934	178,337	Dec 12 08:44 PM
Young Jonathan	Chief Operating Officer	Dec 10 '24	Sale	30.79	2,503	77,067	203,783	Dec 12 08:38 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 10 '24	Sale	30.79	925	28,481	17,858	Dec 12 08:29 PM
Yale Catriona	Chief Development Officer	Dec 10 '24	Sale	30.79	2,810	86,520	71,348	Dec 12 08:28 PM
White William Richard	Chief Financial Officer	Dec 10 '24	Sale	30.79	2,817	86,735	38,335	Dec 12 08:26 PM
Cheng Andrew	President and CEO	Dec 10 '24	Sale	30.79	7,855	241,855	597,562	Dec 12 08:24 PM
Timothy Rolph	Officer	Dec 10 '24	Proposed Sale	30.79	25,000	769,750		Dec 10 04:25 PM
Cheng Andrew	President and CEO	Dec 02 '24	Option Exercise	21.10	25,000	527,500	630,417	Dec 04 07:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience